Results 1 to 10 of about 5,138,951 (296)
Some of the next articles are maybe not open access.
Annual Review of Medicine, 1988
Despite their widespread use in patients with acute myocardial infarction, all currently available thrombolytic agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications.
D, Collen, D C, Stump, H K, Gold
+7 more sources
Despite their widespread use in patients with acute myocardial infarction, all currently available thrombolytic agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications.
D, Collen, D C, Stump, H K, Gold
+7 more sources
Annals of Emergency Medicine, 1993
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks.
Eisenberg, M. +5 more
openaire +3 more sources
All patients with symptoms and ECG findings suggestive of acute myocardial infarction (AMI) should be considered for treatment with thrombolytic agents. The decision to use thrombolytic therapy is a clinical judgment based upon a weighing of the potential benefits versus the possible risks.
Eisenberg, M. +5 more
openaire +3 more sources
Emergency Medicine Clinics of North America, 1995
If the electrocardiogram is diagnostic of acute myocardial infarction (AMI) in the patient complaining of typical chest pain, then indications and contraindications for thrombolytic therapy must be assessed immediately. The goal is to administer a thrombolytic agent within 30 to 60 minutes of presentation to the emergency department.
G P, Young, J R, Hoffman
openaire +3 more sources
If the electrocardiogram is diagnostic of acute myocardial infarction (AMI) in the patient complaining of typical chest pain, then indications and contraindications for thrombolytic therapy must be assessed immediately. The goal is to administer a thrombolytic agent within 30 to 60 minutes of presentation to the emergency department.
G P, Young, J R, Hoffman
openaire +3 more sources
Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.
Current pharmaceutical design, 2019BACKGROUND Thromboembolic ischemic stroke, which is mainly caused by hypertension, as well as plasma dyslipidemia, arterial fibrillation and diabetes, is a leading cause of death in the US and other countries.
K. Shibata +4 more
semanticscholar +1 more source
Blood Reviews, 1989
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
The accepted role for thrombolytic therapy has until recently been limited because of its complexity and side-effects. It has generally been reserved for use systemically in a limited number of patients with acute, major pulmonary embolism or iliofemoral venous thrombosis, and locally in some patients with acute, peripheral arterial occlusion.
openaire +2 more sources
Monitoring thrombolytic therapy
Progress in Cardiovascular Diseases, 1992HROMBOLYTIC THERAPY for acute myocardial infarction (MI) now represents the standard of care for many patients. A large number of clinical trials have demonstrated improvement in survival and cardiac function following treatment of acute MI with thrombolytic agents,‘.’ and the use of thrombolytic therapy is rapidly spreading to community hospitals.
E G, Bovill, R, Becker, R P, Tracy
openaire +2 more sources
Blood Reviews, 2001
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +2 more sources
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +2 more sources